This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer (ZBH) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.
Zimmer (ZBH) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is likely to maintain the current high on a number of favorable factors.
Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.
Zimmer Biomet (ZBH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.57% and 1.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More
by Urmimala Biswas
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
In Spine & CMF, Zimmer Biomet (ZBH) is witnessing slowdown in growth due to difficult comps.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.
Align Technology Inks Distribution Deal With Zimmer Biomet
by Zacks Equity Research
This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.
Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line
by Zacks Equity Research
Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.
Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care
by Zacks Equity Research
Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.
Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe
by Zacks Equity Research
With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.
Why Is Zimmer (ZBH) Up 7.9% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZBH vs. MDT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Zimmer Biomet Wins Nod for Spinal Teather to Treat Scoliosis
by Zacks Equity Research
Zimmer Biomet's (ZBH) AVBT solution, The Tether, uses a solid, flexible cord in place of traditional metal rods to pull on the outside of a scoliosis curve.
BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss
by Zacks Equity Research
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
by Zacks Equity Research
Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.
Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.52% and 0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ZBH vs. MDT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Why Earnings Season Could Be Great for Zimmer Biomet (ZBH)
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
by Zacks Equity Research
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.